Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anitalei Alexio

Nurse Practitioner Aiea, HI Nurse Practitioner

NPI 1639154750 CMS profile 11222329

98-199 Kamehameha Hwy # C10b, Aiea, HI 96701

Open in the dashboard

General payments

$11,433

498 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anitalei Alexio of Aiea, HI is reported in the CMS Open Payments database as having received $11,433 across 498 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,086 82
2024 General $2,455 94
2023 General $1,209 61
2022 General $1,884 76
2021 General $3,799 185

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anitalei Alexio
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Anitalei Alexio were reported at $2,086. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Anitalei Alexio Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $3,799 $135 $40–$426 $132
2022 $1,884 $152 $48–$470 $149
2023 $1,209 $166 $54–$529 $160
2024 $2,455 $173 $55–$556 $164
2025 $2,086 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,666 44 payments
  2. Novo Nordisk Inc $1,521 95 payments
  3. Lilly USA, LLC $1,357 52 payments
  4. Amgen Inc. $1,227 61 payments
  5. AbbVie, Inc. $1,070 37 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $1,002 40 payments
  7. Amarin Pharma Inc. $640 40 payments
  8. Genzyme Corporation $528 26 payments
  9. Biohaven Pharmaceuticals, Inc. $511 24 payments
  10. Novartis Pharmaceuticals Corporation $245 15 payments
  11. Other $1,664 64 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,278 494 payments
  2. Education $154 4 payments
Products named General payments · program years 2021–2025
  1. Kerendia $1,002 40 payments
  2. TEZSPIRE $839 16 payments
  3. MOUNJARO $740 26 payments
  4. Ozempic $709 50 payments
  5. DUPIXENT $707 31 payments
  6. Otezla $680 36 payments
  7. RYBELSUS $652 52 payments
  8. Vascepa $640 40 payments
  9. FASENRA $607 19 payments
  10. UBRELVY $543 20 payments
  11. Other $7,471 352 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

498 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record